ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of ImmunityBio, Inc. (NASDAQ:IBRX) have received a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.60.

IBRX has been the topic of a number of recent analyst reports. Piper Sandler raised their target price on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Jefferies Financial Group increased their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 target price on shares of ImmunityBio in a report on Monday. Finally, HC Wainwright increased their price target on ImmunityBio from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday.

ImmunityBio Stock Performance

NASDAQ:IBRX opened at $11.55 on Wednesday. The stock has a 50-day simple moving average of $4.82 and a two-hundred day simple moving average of $3.24. ImmunityBio has a 52-week low of $1.83 and a 52-week high of $12.28. The firm has a market capitalization of $11.38 billion, a PE ratio of -30.39 and a beta of 0.16.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter. Equities analysts forecast that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reports ANKTIVA regulatory/approval expansion and broader global commercial reach, supporting larger addressable market and sales potential. ImmunityBio’s ANKTIVA Approvals Broaden Global Reach And Investor Opportunity
• Positive Sentiment: Management says ANKTIVA drove massive revenue growth—company reported ~700% year‑over‑year revenue increase and new global commercial partnerships covering multiple countries, signaling meaningful commercial traction. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth…
• Positive Sentiment: Q4 results beat revenue and EPS loss expectations (reported loss $0.06 vs. consensus -$0.08; revenue ~$38.3M), which investors view as confirmation that commercial sales are scaling. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Market coverage and outlets highlight ANKTIVA-driven revenue surge and share gains toward a 52‑week high, reinforcing momentum and investor enthusiasm. ImmunityBio Explodes To Near 52-Week High As Bladder Cancer Drug Anktiva Drives Massive 700% Revenue Growth
• Positive Sentiment: An analyst shop (D. Boral Capital) reaffirmed a “buy” and set a $23 price target, providing an actionable upside thesis for price momentum. Benzinga
• Neutral Sentiment: Founder Dr. Patrick Soon‑Shiong will present at high‑profile cancer summits — visibility and credibility boost but not an immediate revenue driver. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute…
• Neutral Sentiment: Chairman commentary and press pieces tease multi‑year ANKTIVA expansion and potential future indications; positive for sentiment but speculative for near‑term fundamentals. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans…
• Negative Sentiment: Despite the revenue jump, the company remains unprofitable (negative EPS and a current-year analyst consensus loss), which keeps valuation and execution risk elevated for long‑term investors. ImmunityBio Q4 Press Release

Insider Activity

In related news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Barry J. Simon sold 165,000 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.25, for a total value of $1,691,250.00. Following the completion of the transaction, the director directly owned 2,925,821 shares in the company, valued at approximately $29,989,665.25. This represents a 5.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 426,967 shares of company stock valued at $3,565,662 in the last quarter. 69.48% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ImmunityBio

Hedge funds have recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ boosted its holdings in shares of ImmunityBio by 347.7% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 1,324,871 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,028,921 shares during the period. Armistice Capital LLC bought a new stake in ImmunityBio in the second quarter worth $20,497,000. AlphaCore Capital LLC bought a new stake in ImmunityBio in the second quarter worth $7,854,000. Geode Capital Management LLC boosted its stake in ImmunityBio by 34.7% during the second quarter. Geode Capital Management LLC now owns 5,777,269 shares of the company’s stock worth $15,254,000 after buying an additional 1,487,849 shares during the period. Finally, CWM LLC increased its position in ImmunityBio by 849.2% during the second quarter. CWM LLC now owns 48,715 shares of the company’s stock valued at $129,000 after acquiring an additional 43,583 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.